[HTML][HTML] Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian …
N Thielen, B van der Holt, JJ Cornelissen… - European journal of …, 2013 - Elsevier
Background Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
[PDF][PDF] Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease
A Franceschino, L Tornaghi, R Piazza… - …, 2006 - haematologica.org
Imatinib induces complete cytogenetic remissions (CCR) in over 75% of patients with
chronic myeloid leukemia (CML) treated at diagnosis, while in early chronic phase. 1 …
chronic myeloid leukemia (CML) treated at diagnosis, while in early chronic phase. 1 …
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
[HTML][HTML] What challenges remain in chronic myeloid leukemia research?
AM Carella, S Branford, M Deininger, FX Mahon… - …, 2013 - ncbi.nlm.nih.gov
Editorials and Perspectives haematologica| 2013; 98 (8) 1169 four years. These results
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …
[HTML][HTML] Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.
D Verma, HM Kantarjian, J Shan, S O'Brien, A Verma… - Blood, 2009 - Elsevier
Abstract Abstract 505 Background: Therapy with imatinib and other tyrosine kinase inhibitors
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …
Is imatinib maintenance required for patients with relapse chronic myeloid leukemia post-transplantation obtaining CMR? a pilot retrospective investigation
H Jin, Y Xiong, J Sun, Y Zhang, F Huang, H Zhou… - PLoS …, 2013 - journals.plos.org
Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous
leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite …
leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
Effects of deeper molecular responses on outcomes in chronic myeloid leukemia patients in chronic phase treated with Imatinib Mesylate
IK Atagunduz, T Toptas, R Deniz, O Kara, A Eser… - … Myeloma and Leukemia, 2017 - Elsevier
Background The prognostic significance of complete cytogenetic response (CCyR) is well
defined in patients with chronic phase chronic myeloid leukemia treated with imatinib as first …
defined in patients with chronic phase chronic myeloid leukemia treated with imatinib as first …
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have …
P Rousselot, A Charbonnier… - Journal of clinical …, 2014 - ascopubs.org
Purpose More than half of patients with chronic-phase chronic myelogenous leukemia (CP-
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …